Durable Response to Combined Osimertinib and Pralsetinib Treatment for Osimertinib Resistance Due to Novel Intergenic ANK3-RET Fusion in EGFR -Mutated Non-Small-Cell Lung Cancer.
Edyta Maria UrbanskaJens B SørensenLinea C MelchiorJunia C CostaEric Santoni-RugiuPublished in: JCO precision oncology (2022)